ArticleCritical care explorations2021

Efficacy and Safety of Vilobelimab (IFX-1), a Novel Monoclonal Anti-C5a Antibody, in Patients With Early Severe Sepsis or Septic Shock-A Randomized, Placebo-Controlled, Double-Blind, Multicenter, Phase IIa Trial (SCIENS Study).

Michael Bauer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.